At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Mucinex®drug
Likely dose
Mucinex® 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Single-dose, Randomized, 2-way Cross-over Study Designed to Examine the Relative Bioavailability of Guaifenesin When a Mucinex Extended Release 600 mg Bi-layer Tablet is Taken Under Fasted Compared to Fed Conditions in Normal Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Mucinex® for Healthy Subjects. Completed, enrolled 36 participants.
Detailed Summary
Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
Primary CompletionAug 2013
First PostedAug 2018
TodayJul 2026
First PostedAug 28, 2018
Enrollment StartMay 29, 2013
Primary CompletionAug 7, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.8 years ago
Interventions
Mucinex®drug
Mucinex® 600 mg ER bi-layer tablets